Alto Neuroscience GAAP EPS of -$0.56 beats by $0.10

• Alto Neuroscience press release (NYSE:ANRO): Q1 GAAP EPS of -$0.56 beats by $0.10.

• As of March 31, 2025, ANRO had cash, cash equivalents, and restricted cash of ~$161.3M. ANRO expects its cash balance to support planned operations into 2028.

More on Alto Neuroscience

• Seeking Alpha’s Quant Rating on Alto Neuroscience
• Historical earnings data for Alto Neuroscience
• Financial information for Alto Neuroscience